Company AEterna Zentaris Inc. Nasdaq

Equities

CA0079753038

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

Sector Other Biotechnology & Medical Research

Inactive Instrument

End-of-day quote Nasdaq Other stock markets
- ^USD	-

Jul. 02	Mannatech Names James Clavijo Finance Chief	MT
Jun. 13	Aeterna Zentaris Inc. Announces Last Patient Last Visit in Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency	CI

Aeterna Zentaris Inc. is a Canada-based specialty biopharmaceutical company. The Company is developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. The Company's lead product, macimorelin (Macrilen, Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also leveraging the clinical and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD). It is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources, which are used in cosmeceutical products, such as oat beta glucan and avenanthramides, and is being developed as potential nutraceuticals and/or pharmaceuticals. Its therapeutic development pipeline includes AIM Biologicals, AEZS-150 and AEZS-1.

CAD in Million	2022	Weight	2023	Weight	Delta
Biopharmaceutical 100.0 %	7	100.0 %	6	100.0 %	-17.32%

CAD in Million	2022	Weight	2023	Weight	Delta
Switzerland 96.0 %	7	95.7 %	6	96.0 %	-17.04%
Ireland 2.7 %	0	1.5 %	0	2.7 %	+54.25%
Other 1.1 %	0	0.1 %	0	1.1 %	+1,558.79%
Denmark 0.2 %	0	2.8 %	0	0.2 %	-92.87%

Managers	Title	Age	Since
Gilles Gagnon CEO	Chief Executive Officer	70	98-12-31
Giuliano La Fratta DFI	Director of Finance/CFO	-	22-01-23
Patricia Zahn ADM	Chief Administrative Officer	-	15-09-30
Nicola Ammer CTO	Chief Tech/Sci/R&D Officer	-	14-01-31
Michael Teifel CTO	Chief Tech/Sci/R&D Officer	-	03-12-31
Matthias Gerlach PRN	Corporate Officer/Principal	-	00-12-31
Eckhard Guenther PRN	Corporate Officer/Principal	-	05-12-31

Members of the board	Title	Age	Since
Gilles Gagnon CEO	Chief Executive Officer	70	19-12-31
Peter Edwards BRD	Director/Board Member	62	20-05-14
Dennis Turpin BRD	Director/Board Member	-	21-05-04
Carolyn Egbert CHM	Chairman	-	12-07-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	3,061,684	3,012,875 ( 98.41 %)	0	98.41 %

Name	Equities	%	Valuation
Goodwood, Inc. 3.680 %	44,670	3.680 %	432 852 $
Gilles Gagnon 3.457 %	41,962	3.457 %	406 612 $
Morgan Stanley Capital Services LLC 0.3332 %	4,045	0.3332 %	39 196 $
Citadel Securities GP LLC 0.3262 %	3,960	0.3262 %	38 372 $
BMO Bank NA (Investment Management) 0.2283 %	2,771	0.2283 %	26 851 $
William Li 0.1975 %	2,397	0.1975 %	23 227 $
Ulrich Kosciessa 0.1522 %	1,848	0.1522 %	17 907 $
Klaus Wolfgang Paulini 0.0865 %	1,050	0.0865 %	10 175 $
Edmond De Rothschild Holding SA /13F Subfiler/ 0.0824 %	1,000	0.0824 %	9 690 $
Stacy Prefontaine 0.0632 %	767	0.0632 %	7 432 $

Æterna Zentaris, Inc.

222 Bay Street Suite 3000

M5K 1E7, Toronto

http://www.zentaris.com

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+18.97%	45.34B
LONZA GROUP AG	+41.98%	40.42B
IQVIA HOLDINGS INC.	-10.06%	37.92B
ALNYLAM PHARMACEUTICALS, INC.	+31.15%	31.75B
CELLTRION, INC.	-7.79%	27.71B
ICON PUBLIC LIMITED COMPANY	+13.32%	26.52B
UNITED THERAPEUTICS CORPORATION	+43.05%	13.96B
MEDPACE HOLDINGS, INC.	+31.28%	12.44B
BIO-TECHNE CORPORATION	-7.41%	11.26B

Other Biotechnology & Medical Research